Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Concomitant treatment with ixekizumab (Taltz) and tirzepatide (Zepbound) was associated with broader changes in 

-associated, immune, and metabolic biomarkers compared with ixekizumab alone in adults with psoriasis and obesity, according to new exploratory data from the phase 3b TOGETHER-PsO trial. The prespecified analysis was presented at the 

2026 Fall Clinical Dermatology Conference

 in Las Vegas and announced by Eli Lilly and Company on October 9, 2026.

According to Lilly, approximately 61% of people with psoriasis in the US also have obesity or overweight with at least 1 weight-related comorbidity. The company stated the findings suggest an immunometabolic relationship between the 2 conditions, which are often managed through separate treatment approaches.

The new analysis builds on previously reported TOGETHER-PsO results. In those data, concomitant ixekizumab and tirzepatide delivered superior skin clearance and clinically meaningful weight reduction versus ixekizumab alone at the Week 36 primary endpoint, with improvements maintained or further improved through Week 52.

What Did the TOGETHER-PsO Biomarker Analysis Show?

TOGETHER-PsO (NCT06588283) is a 52-week, randomized, multicenter, assessor-blinded, open-label phase 3b study. The trial enrolled adults with moderate-to-severe plaque psoriasis and either obesity (body mass index [BMI] of 30 kg/m² or higher) or overweight (BMI of 27 to less than 30 kg/m²) with at least 1 additional weight-related comorbid condition. A total of 274 participants were randomized 1:1 to subcutaneous ixekizumab alone or in combination with tirzepatide, and patients in both arms received counseling on a reduced-calorie diet and increased physical activity. The primary endpoint was the proportion of participants achieving both Psoriasis Area and Severity Index (PASI) 100 and at least 10% weight reduction at Week 36.

The exploratory analysis evaluated circulating proteins and blood gene expression to characterize biological changes in each arm. At Week 36, changes in psoriasis-specific, immune, and metabolic biomarkers in both arms were consistent with the known effects of each medication in their approved indications.

Combination therapy was associated with broader biomarker responses beginning as early as Week 12, according to Lilly. By Week 36, 482 proteins were differentially expressed with the combination versus 140 with ixekizumab alone, and 467 genes were differentially expressed versus 16, respectively.

How Might Neutrophil Activity Explain Added Skin Clearance?

The analysis also showed greater reductions in inflammatory immune activity with combination therapy compared with ixekizumab monotherapy, including changes in neutrophil-related markers. Changes in a subset of neutrophil-associated markers mediated a portion of the additional PASI response observed with the combination versus ixekizumab alone.

James G. Krueger, MD, PhD, professor and laboratory head at The Rockefeller University, said the analysis offers new insight into the potentially connected immune and metabolic biology of psoriasis and obesity. He noted the most compelling finding was the identification of differences in inflammatory pathways when patients received concomitant treatment for both conditions, and highlighted immunometabolic health as an important area for continued research.

Mark Genovese, MD, senior vice president of Lilly Immunology development, said the broader biomarker changes, including those associated with skin clearance, may point to a meaningful relationship between immune and metabolic biology. Together with prior clinical outcomes, he said, the findings support a more comprehensive approach to psoriasis care addressing obesity in patients with both conditions.

Safety in the earlier TOGETHER-PsO results was consistent with the known profiles of each medication, according to Lilly.

Editor’s note: This summary has been edited for grammar and clarity using artificial intelligence tools.

Eli Lilly and Company. New phase 3b data on Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity. Published October 9, 2026. Accessed October 9, 2026. 

https://investor.lilly.com/news-releases/news-release-details/new-phase-3b-data-lillys-taltz-ixekizumab-and-zepbound-0

A study of ixekizumab (LY2439821) and tirzepatide (LY3298176) in adults with moderate-to-severe plaque psoriasis and obesity or overweight (TOGETHER-PsO). ClinicalTrials.gov identifier: NCT06588283. Updated 2026. Accessed October 9, 2026. 

https://clinicaltrials.gov/study/NCT06588283

Articles

New TOGETHER-PsO data show ixekizumab plus tirzepatide drove broader immune and metabolic biomarker changes than ixekizumab alone in psoriasis and obesity.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Ixekizumab, Tirzepatide Broaden Biomarker Effects in Psoriasis, Obesity

Daxdilimab, an anti-ILT7 antibody depleting plasmacytoid dendritic cells (pDCs), reduced disease activity vs placebo in 

moderate to severe discoid lupus erythematosus (DLE)

European Academy of Dermatology and Venereology (EADV) Congress 2026

Treatment options for DLE remain limited, with clinicians relying largely on older therapies, few of which have been formally studied in randomized trials. pDCs accumulate in the lesional skin of patients with cutaneous lupus and drive type I interferon activity.¹,

 Daxdilimab, developed by Amgen, binds immunoglobulin-like transcript 7 (ILT7), a surface protein expressed only on pDCs, reducing pDC numbers in tissue and blood.¹

“There’s a need for new treatments for discoid lupus and for cutaneous lupus in general,” said Victoria Werth, MD, professor of dermatology at the University of Pennsylvania, in an interview with HCPLive at EADV. “I There has not been a single approved drug in [roughly] 80 years. It’s significant to get approval of new drugs for patients who have refractory disease.”

Daxdilimab Improves Discoid Lupus in Phase 2, With Victoria Werth, MD

Daxdilimab Efficacy in Treatment-Refractory Discoid Lupus

The multicenter, randomized, double-blind, placebo-controlled phase 2 trial enrolled adults aged 18 to 75 years with chronic, treatment-refractory DLE lasting ≥ 6 months.¹ Eligible patients had active disease, defined as a Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score of ≥ 8, and no systemic features.¹

In total, 72 patients were randomized 1:1:1 to low-dose daxdilimab (n = 24), high-dose daxdilimab (n = 23), or placebo (n = 25). Dosing occurred every 4 weeks from day 1 through week 20.¹ Patients had a mean age of 48.8 years and 69.4% were female. Mean baseline scores were 15.2 for CLASI-A and 3.1 for the Cutaneous Lupus Activity Investigator’s Global Assessment (CLA-IGA).¹

Both doses met the primary endpoint of mean change in CLASI-A from baseline to week 24. The least squares mean difference vs placebo was –6.0 for low-dose daxdilimab (90% CI, –8.7 to –3.2; 

 =.0005) and –5.7 for high-dose daxdilimab (90% CI, –8.5 to –2.9; 

 =.0012).¹ Separation from placebo emerged as early as week 4, and Werth noted improvement continued through the 24-week study period.

Daxdilimab Secondary Endpoints and Safety Profile in DLE

At week 24, adjusted CLASI-50 response rates reached 61.7% with low-dose daxdilimab (

 =.0037) and 62.1% with high-dose daxdilimab (

 =.0044), compared with 23.7% with placebo.¹ Adjusted CLA-IGA 0/1 response rates were 60.3% (

 =.0007), respectively, vs 8.9% with placebo.¹

“We know a CLASI-50 is significant from a patient perspective,” Werth said. “When you actually look at the patients who got treated and some of the photography, you can really see the improvement is quite dramatic.”

No serious adverse events or deaths were reported. Treatment-emergent adverse events occurred in 58.3%, 56.5%, and 60% in the low-dose, high-dose, and placebo groups, respectively. One patient receiving high-dose daxdilimab discontinued because of grade 3 arthralgia.¹

Diarrhea occurred in 3 patients (13%) in the high-dose group and none in the other arms. Nasopharyngitis was more frequent with placebo (16%) than with daxdilimab.¹ Werth added no cases of herpes zoster were observed, a longstanding concern with therapies targeting interferon production.

Where pDC-Targeted Therapy Could Fit in DLE Treatment

Low- and high-dose daxdilimab met the primary endpoint, reducing CLASI-A by 6.0 and 5.7 points vs placebo at week 24.

CLASI-50 response rates exceeded 60% with both doses vs 23.7% with placebo, with response seen by week 4.

No serious adverse events, deaths, or herpes zoster cases were reported; 1 patient discontinued because of arthralgia.

Werth described 2 pDC-directed agents in development. Daxdilimab depletes pDCs, whereas litifilimab, an antibody against blood dendritic cell antigen 2 (BDCA2), triggers receptor internalization and downregulates pro-inflammatory pDC activity.

Given the rapid onset of response and the safety profile observed, Werth said daxdilimab and other pDC-targeting drugs could fit early in the DLE treatment cascade. She also pointed to agents targeting toll-like receptor (TLR) 7/8 entering phase 3. She credited FDA acceptance of the CLASI as a primary skin outcome with enabling the current wave of cutaneous lupus trials.

“There will be a lot of work to do to understand the nuances between these drugs,” Werth said.

Werth V, Merola JF, Chong B, et al. Daxdilimab in moderate-to-severe discoid lupus erythematosus: efficacy and safety results from a phase 2, randomised, placebo-controlled trial. Abstract 136. Presented at: EADV Congress 2026; September 30–October 3, 2026; Vienna, Austria.

Karnell JL, Wu Y, Mittereder N, et al. Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus. 

Videos

Both doses of the anti-ILT7 antibody daxdilimab reduced CLASI-A scores vs placebo at week 24 in moderate-to-severe, treatment-refractory discoid lupus.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

When should clinicians choose an oral JAK inhibitor over topical ruxolitinib for vitiligo?


Hamzavi favors oral therapy when vitiligo affects more than 10% of body surface area or shows signs of instability, while topical ruxolitinib suits localized, stable disease.

What are the clinical markers of unstable vitiligo?


Trichrome lesions, confetti-like depigmentation, and koebnerization are 3 physical examination findings Hamzavi identified as signals of progressive disease.

Which patients may be poor candidates for oral JAK inhibitors?


Patients with active cardiovascular risk, high body mass index, smoking history, a strong family history of cardiovascular disease, or very high cholesterol may warrant caution, according to Hamzavi.

Janus kinase (JAK) inhibitors have reshaped the treatment of 

, with topical and oral agents now filling distinct roles, according to Iltefat Hamzavi, MD, of Henry Ford Health.

 in Las Vegas, Hamzavi spoke about key takeaways from his session, “Seminar-In-Depth: Is This the JAK We’re Looking For? The Evolving Role of JAK Inhibitors in Vitiligo.”

Topical vs Oral JAK Inhibitors in Vitiligo, With Iltefat Hamzavi, MD

Where Do JAK Inhibitors Fit in Vitiligo Treatment?

Hamzavi explained topical JAK inhibitors, led by 

-approved ruxolitinib cream, have become the preferred agent largely because of their strong safety profile. Before their approval, clinicians relied on off-label topical calcineurin inhibitors and steroids without long-term safety data, a significant gap given vitiligo often requires years of treatment. Long-term trials, data on combining topical JAK inhibitors with phototherapy, and exposure in hundreds of thousands of patients have since clarified what to expect and how to manage adverse effects.

Oral JAK inhibitors, including upadacitinib, ritlecitinib, and povorcitinib, have completed large phase 3 trials involving nearly 3000 patients, with few systemic adverse effects observed, Hamzavi said. He advised caution in patients with active cardiovascular risk, high body mass index, smoking history, a strong family history of cardiovascular disease, or very high cholesterol. For most patients, particularly younger individuals, he said oral agents may stabilize vitiligo more effectively than prior options for rapidly progressive disease, such as oral steroids or methotrexate.

Which Patients Are Candidates for Oral vs Topical JAK Therapy?

According to Hamzavi, topical ruxolitinib suits localized disease affecting less than 10% of body surface area without markers of instability. Clinicians should look for 3 physical findings signaling unstable, progressive disease: trichrome lesions, confetti-like depigmentation, and koebnerization.

Once disease exceeds 10% of body surface area, the volume of cream required raises the risk of adverse effects, making oral therapy the better choice, he said. Oral agents are also favored for unstable disease. Because melanocytes turn over slowly and repigmentation can take a year, Hamzavi emphasized preventing further depigmentation and its psychosocial impact.

Editor’s note: This summary has been edited for grammar and clarity using artificial intelligence tools. Hamzavi has disclosed serving as a consultant for AbbVie, Pfizer, Incyte, UCB, Boehringer Ingelheim, Sonoma, Merck, Takeda,Teva, Novartis, Jansen, Avita, Galderma, Vimela, and Almirall; an investigator for Pfizer, Incyte, Avita, L'Oréal/La Roche-Posay, ITN, and AbbVie; and a board member and past president of the Hidradenitis Suppurativa and Global Vitiligo foundations.

Hamzavi I. Seminar-in-depth: is this the JAK we’re looking for? The evolving role of JAK inhibitors in vitiligo. Presented at: 2026 Fall Clinical Dermatology Conference; October 8-11, 2026; Las Vegas, NV.

Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445-1455. doi:10.1056/NEJMoa2118828

HCPLive. Ritlecitinib improves repigmentation in nonsegmental vitiligo phase 3 data. 

https://www.hcplive.com/view/ritlecitinib-improves-repigmentation-nonsegmental-vitiligo-phase-3-data

. Published July 30, 2026. Accessed October 9, 2026.

Iltefat Hamzavi, MD, explains how topical and oral JAK inhibitors fit into vitiligo care and which patients are the best candidates for each approach.

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Kimberly Brown, MD, is division chief of gastroenterology and hepatology and the Associate Medical Director of the Henry Ford Hospital Transplant Institute at Henry Ford Hospital. She is also a Professor of Medicine at Wayne State University

Jasmohan Bajaj, MD, is a Professor of Medicine in the Division of Gastroenterology, Hepatology, and Nutrition at Virginia Commonwealth University and the Richmond VA Medical Center in Richmond, Virginia.

Liver Lineup: Updates & Unfiltered Insights

Nancy Reau, MD, of Rush University Medical Center, and Kim Brown, MD, of Henry Ford, welcome Jasmohan Bajaj, MD, MS, of Virginia Commonwealth University and the Richmond VA Medical Center, to discuss the new American College of Gastroenterology (ACG) guideline on hepatic encephalopathy (HE). This first segment of a 3-part series covers what changed in diagnosis, inpatient care, and recurrence prevention.

Liver Lineup: New ACG Hepatic Encephalopathy Guidelines Explained

How Does the New ACG Guideline Change Hepatic Encephalopathy Diagnosis in Clinic?

Bajaj opened by noting patients are older and more comorbid than a decade ago, which complicates what looks like HE. The guideline widens its focus to caregivers, finances, and a new social infrastructure axis, since a patient-only focus misses roughly 50% of the burden, he said.¹

It also adds structured steps for three conditions capable of mimicking or worsening HE. Alcohol use, obstructive sleep apnea, and mild cognitive impairment or dementia each get a defined clinic check. Bajaj noted most sleep disturbance in patients with cardiometabolic disease now traces to sleep apnea, not HE, and he wants to avoid labeling those patients with HE and committing them to lactulose for life. He has described the covert stage as often ignored or confused for overt disease.²

For clinic workflow, Bajaj pointed to the AUDIT-C, which takes about 2 minutes, the STOP-BANG for suspected sleep apnea, and the Mini-Mental State Examination, a rarer positive.

On ammonia, Bajaj was direct. Levels rise in cirrhosis, so a high value in an alert, asymptomatic outpatient does not establish HE, and ammonia alone should neither diagnose nor exclude it.¹ HE remains a clinical diagnosis of exclusion built on patient report and caregiver observations such as near misses, car accidents, and trouble at work.

When other causes are excluded and symptoms persist, the guideline outlines a theragnostic lactulose trial. Bajaj advised starting at a low dose, titrating by the Bristol stool scale to avoid gas and excess stools, and reassessing in person at roughly eight weeks. He estimated about 80% of patients improve and 10% to 15% fail a true trial. For those patients, he suggested neuropsychology referral through primary care, stopping lactulose, and removing the HE diagnosis from the chart because of possible medicolegal consequences.

How Should Hospitalized Patients With Hepatic Encephalopathy Be Managed, and When Should Rifaximin Start?

Brown noted inpatient teams recognize HE more readily because cirrhosis is already known. Bajaj reiterated the guideline's call to look past HE for other causes, including alcohol and stroke. Once HE is suspected, priorities include preventing aspiration pneumonia and hypernatremia, with grade 3 or higher encephalopathy ideally managed in a monitored setting.

Precipitants are also shifting. Bajaj said acute kidney injury and infection now outpace GI bleeding as common triggers. Identifying the trigger is the second step, followed by therapy.

The notable change from prior AASLD and EASL guidance is earlier rifaximin alongside lactulose in the inpatient setting, because patients tolerate it and the combination may work better than lactulose alone.¹ For grade 3 episodes, Bajaj favored lactulose enemas over oral dosing, which risks aspiration.

Because specialists often see patients a day or two after admission, Bajaj urged teaching ED, house, and support staff the basics. These include timely paracentesis to exclude spontaneous bacterial peritonitis, monitored or ICU transfer for grade 3 or higher, and early lactulose. ACG guidelines come with a one-page handout distilling the critical points for posting on units.

How Can Clinicians Prevent Recurrent Hepatic Encephalopathy and Avoid Readmission?

Reau asked what the guideline recommends after the patient clears. Bajaj called recurrence prevention the most important part of HE care and the reason the guideline added social infrastructure as a fifth axis. He estimated 95% of HE admissions could be preventable with 10 to 15 extra minutes spent with the patient, caregiver, family, and pharmacist.

After a first episode, Bajaj recommended a family meeting. He described a recent 35-minute session for a 75-year-old patient and noted the discussion is far harder when the patient is a working breadwinner who drives. Families should learn early warning signs so they do not wait until the patient is comatose, decide whether they are comfortable titrating lactulose, and clarify who checks on a patient living alone.

If the patient has not fully recovered, Bajaj advised at least one CT or MRI, rather than the ultrasound used for HCC surveillance, to look for spontaneous portosystemic shunts. Patients who recur despite adherence and have a relatively low MELD score are candidates for embolization. He added transplant listing deserves consideration at the first episode, given

Editors’ note: Relevant disclosures for 

 include AbbVie, Gilead, Salix, Arbutus, and VIR. Relevant disclosures for 

 include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal. Relevant disclosures for 

 include Bausch/Salix, Grifols, Cosmo, and others.

Bajaj JS, Jakab SS, Jesudian AB, et al. ACG clinical guideline: hepatic encephalopathy. 

. 2026;121(3):588-618. doi:10.14309/ajg.0000000000003899

Hillenbrand A. ACG issues new hepatic encephalopathy guidelines for diagnosis, treatment, nutrition, and transplant, with Jasmohan Bajaj, MD, MS. 

. March 24, 2026. Accessed October 9, 2026. 

https://www.hcplive.com/view/acg-issues-new-hepatic-encephalopathy-guidelines-for-diagnosis-treatment-nutrition-and-transplant-with-jasmohan-bajaj-md-ms-

Podcasts

Jasmohan Bajaj, MD, joins Nancy Reau, MD, and Kim Brown, MD, to review what is new in the ACG hepatic encephalopathy guideline.

Hepatology

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Hosted by Nancy Reau, MD, and Kimberly Brown, MD, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice.

Liver Lineup: What's New in the ACG Hepatic Encephalopathy Guideline

Brepocitinib (Lisraya), an oral selective tyrosine kinase 2 (TYK2)/Janus kinase 1 (JAK1) inhibitor, produced rapid, dose-dependent reductions in 

 disease activity versus placebo in the phase 2 portion of the BEACON trial.

 Aaron R. Mangold, MD, professor of dermatology and medical director of the Office of Clinical Trials at Mayo Clinic in Arizona, discussed the findings with 

Mangold presented the prespecified interim analysis at the 

 in Vienna, Austria. BEACON (NCT06978725) is an ongoing phase 2/3 trial randomizing adults with biopsy-proven active disease and a Cutaneous Sarcoidosis Activity and Morphology Instrument-Activity (CSAMI-A) score of 10 or greater to once-daily brepocitinib 45 mg (n = 13), brepocitinib 15 mg (n = 11), or placebo (n = 7), with any oral corticosteroids tapered off by week 8.

already approved for adults with dermatomyositis

, is the first targeted therapy with randomized, placebo-controlled efficacy data in the disease.

Brepocitinib Improves Cutaneous Sarcoidosis by Week 4: Aaron Mangold, MD

"What you see specifically in the highest dose of brepocitinib is essentially all patients, 100% of them, say, 'I'm better on therapy,' which I think really, number one, aligns with the clinical assessments showing really dramatic improvement. But number two gets really critically as to why do we treat people, and it is to make them feel better," Mangold said.

At week 16, mean CSAMI-A reduction was 22.3 points with brepocitinib 45 mg versus 0.7 points with placebo (

 < .0001), with separation from placebo evident by week 4.

 The 45 mg dose also yielded higher rates of Cutaneous Sarcoidosis Activity–Investigator Global Assessment clear or almost clear (9/13 [69%] vs 0/7 [0%]; 

 = .0047), 50% or greater CSAMI-A improvement (10/13 [77%] vs 0/7 [0%]; 

 = .0031), and CSAMI-A below 5 (8/13 [62%] vs 0/7 [0%]; 

Mean Skindex-16 scores improved by 24 points in the 45 mg arm versus a 9-point worsening with placebo (

 All 13 patients receiving 45 mg reported improvement on the Patient Global Impression of Change, compared with 2/7 (29%) placebo recipients (

No deaths, serious adverse events, malignancies, major adverse cardiovascular events, venous thromboembolic events, or viral reactivations occurred.¹ Mangold noted the 31-patient study was not designed to characterize overall safety, pointing instead to the larger brepocitinib exposure across other indications, including dermatomyositis. The 45 mg dose is advancing into the phase 3 portion of BEACON; these data come from a congress abstract and have not been peer reviewed.

Relevant disclosures for Mangold include arGEN-X, Bristol Myers Squibb, Boehringer Ingelheim, Clarivate, Incyte, Priovant, and Sun Pharma.

Rosenbach M, Shields B, Coates M, et al. Efficacy and safety of brepocitinib in cutaneous sarcoidosis: results from the phase II portion of the randomized, double-blind, placebo-controlled BEACON trial. Abstract 145. Presented at: EADV Congress 2026; September 30–October 3, 2026; Vienna, Austria.

A study of brepocitinib in adults with cutaneous sarcoidosis (BEACON). ClinicalTrials.gov identifier: NCT06978725. Updated August 25, 2026. Accessed October 9, 2026. https://clinicaltrials.gov/study/NCT06978725

Aaron Mangold, MD, discusses phase 2 BEACON data on brepocitinib, a TYK2/JAK1 inhibitor, in cutaneous sarcoidosis presented at EADV 2026.

Kunihiro Hattori, PhD, is a mentor with the Japan International Drug Discovery Ecosystem Association. He spent 40 years at Chugai Pharmaceutical. He joined in 1984 and went on to lead the Genome and Antibody Research Department and later the Discovery Research Department. He then served as a fellow and as associate vice president and senior fellow until 2024. From 2017 to 2024, he was also a visiting professor at the Immunology Frontier Research Center at Osaka University. Hattori originated the concept of a bispecific antibody to replace the function of factor VIII and led the research project that produced emicizumab. He earned his PhD from the Graduate School of Pharmaceutical Sciences at Osaka University.

Lasker Award winners Takehisa Kitazawa and Tomoyuki Igawa discuss prophylaxis gains, remaining unmet needs, and lessons for drug discovery.


Hematology

How Emicizumab Changed Hemophilia A Prophylaxis, and What Comes Next

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

In the phase 3 RAPIDe-3 trial published in The Lancet, median time to symptom relief was 1.28 hours with deucrictibant vs more than 12 hours with placebo.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Oral Deucrictibant Speeds Relief of Hereditary Angioedema Attacks

Lasker Award winners Kunihiro Hattori, Takehisa Kitazawa, and Tomoyuki Igawa recount the 2400 variants behind the drug.

Hemophilia A: Why Emicizumab’s Inventors Chose to Mimic Factor VIII

Weltruza requires no loading doses, oral supplementation, or post-injection monitoring, with approval based on the phase 3 SOLARIS trial.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

FDA News

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia

Specialists detail antiarrhythmic use, procedural referral timing, and the atrial remodeling paradox seen with cardiac myosin inhibitors.

Video Series

AF Management in oHCM in Era of Cardiac Myosin Inhibitors

Specialists discuss stroke risk, REMS hospitalization data, and how aficamten's early AFib signal compares against mavacamten.

Understanding Risks Associated with AF in oHCM Management

In this session, Cheri Frey, MD, shared a framework for evaluating skincare products, from ingredient plausibility to clinically meaningful results.

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Andrea Murina, MD, reviewed strategies for optimizing HS biologics, combining therapies, and reconsidering the role of surgery.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Tips on Optimizing HS Biologics, Combinations, and Surgery

HCPLive previews Fall Clinical 2026 in Las Vegas, October 8-11, with key sessions on atopic dermatitis, psoriasis, and vitiligo, plus expert interviews.

Conference Preview: Fall Clinical Dermatology Conference 2026

With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.

Food Allergy

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Latest News

Ixekizumab, Tirzepatide Broaden Biomarker Effects in Psoriasis, Obesity

Daxdilimab Improves Discoid Lupus in Phase 2, With Victoria Werth, MD

Topical vs Oral JAK Inhibitors in Vitiligo, With Iltefat Hamzavi, MD

Liver Lineup: What's New in the ACG Hepatic Encephalopathy Guideline

Brepocitinib Improves Cutaneous Sarcoidosis by Week 4: Aaron Mangold, MD